|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.92 USD | +2.86% |
|
+0.05% | +0.21% |
| 12/02 | Biogen Inc. Announces Board Changes | CI |
| 11/02 | RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.14TCr | |||||
| 5.15TCr | |||||
| 4.43TCr | |||||
| 3.17TCr | - | ||||
| 2.66TCr | - | ||||
| 2.12TCr |
- Stock Market
- Equities
- EXEL Stock
- Charts Exelixis, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition